Filament Health Corp. FLHLF announced that the U. S. Patent and Trademark Office (USPTO) issued a patent that will allow the company to extract and standardize natural psilocybin and associated psychedelic compounds.
Benjamin Lightburn, CEO of the company, commented: “The issuance of Filament's first US patent is a testament to the strength of our drug development platform.”
The company also holds the first-ever Canadian patent for extracting and standardizing natural psilocybin for a public company, as announced in August 2021. The process is undertaken by Filament’s subsidiary, Psilo Scientific.
”Shepherding an application to issuance is different in every country, therefore having our IP validated by more than one government is evidence of our team's talent for innovation by truly diverse criteria,” added Taran Grey, director of intellectual property.
Photo: Courtesy of Marco Allegretti on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.